The molecular spectrum of amyloid-beta (Aβ) in neurodegenerative diseases beyond Alzheimer's disease.

"data s1."

"CONFLICT OF INTEREST STATEMENT Anthony E. Lang has served as an advisor for AbbVie, AFFiRis, Alector, Amylyx, Aprinoia, Biogen, BioAdvance, BlueRock, Biovie, BMS, CoA Therapeutics, Denali, Janssen, Jazz, Lilly, Novartis, Paladin, Pharma 2B, PsychoGenetics, Retrophin, Roche, Sun Pharma, and UCB; received honoraria from Sun Pharma, AbbVie and Sunovion; received grants from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, the Ontario Brain Institute, Parkinson Foundation, Parkinson Canada, and W. Garfield Weston Foundation; is serving as an expert witness in litigation related to paraquat and Parkinson's disease, received publishing royalties from Elsevier, Saunders, Wiley‐Blackwell, Johns Hopkins Press, and Cambridge University Press. Gabor G. Kovacs has served as an advisor for Biogen; received royalty for 5G4 synuclein antibody and publishing royalties from Wiley, Cambridge University Press and Elsevier, received grants from Edmond J Safra Philanthropic Foundation, Rossy Foundation, Michael J. Fox Foundation, Parkinson Canada, Canada, Canada Foundation for Innovation, MSA Coalition, and National Institutes of Health (NIH). The interests listed for Anthony E. Lang and Gabor G. Kovacs have no relevance for the manuscript. Shojiro Ichimata, Koji Yoshida, and Ekaterina Rogaeva do not report any competing interests."

"Canadian Consortium on Neurodegeneration in Aging 10.13039/100015569; Edmond J Safra Philanthropic Foundation; Rossy Family Foundation"